Physician profile
Konstantinos Sdrimas
NPI 1952782534
$81,286.63
in general payments reported to CMS, 2019-2025
17 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $168 · 2021: $203 · 2022: $99.95 · 2023: $196 · 2024: $347 · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $11K · Consulting Fee: $8,755 · Food and Beverage: $2,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,330.00 |
| Travel and Lodging | $11,021.51 |
| Consulting Fee | $8,755.00 |
| Food and Beverage | $2,662.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70,725.51 | 2025 | Breyanzi |
| Kite Pharma, INC. | $8,231.05 | 2025 | Yescarta |
| Celgene Corporation | $492.12 | 2019-2024 | Abecma |
| Seagen INC. | $380.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $359.79 | 2019-2025 | Onglyza, Calquence |
| Legend Biotech USA INC. | $194.96 | 2025 | Carvykti |
| Lilly USA, LLC | $128.07 | 2019 | |
| Genentech USA, INC. | $124.33 | 2019 | |
| Lantheus Medical Imaging, INC. | $115.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Incyte Corporation | $99.95 | 2022 | |
| Amgen INC. | $95.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $71.00 | 2021 | |
| Pfizer INC. | $64.80 | 2019 | |
| Beigene USA, INC. | $56.09 | 2023 | Brukinsa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.51 | 2025 | |
| Janssen Scientific Affairs, LLC | $16.37 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Konstantinos Sdrimas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.